Merck is close to a $1.3 billion deal to buy Eyebiotech, whose lead drug, Restoret, is in development to treat eye conditions including a form of age-related macular degeneration.

https://www.wsj.com/health/pharma/merck-nears-1-3-billion-deal-for-eye-drug-company-eyebio-5b9ce7cb